Research Progress on the Mechanism of Action and Efficacy of Sacubitril/Valsartan in the Treatment of Atrial Fibrillation

心房颤动(简称房颤)是临床常见的心律失常之一，显著增加了心血管事件和死亡的风险。目前维持房颤窦性心律的方法有射频消融术和抗心律失常药物治疗，但药物及手术治疗均存在较高的复发率，难以达到较满意的治疗效果。沙库巴曲缬沙坦作为一种血管紧张素受体–脑啡肽酶抑制剂(ARNI)，可同时抑制脑啡肽酶和阻断血管紧张素受体，现已有研究显示沙库巴曲缬沙坦治疗心力衰竭及高血压的同时，有助于改善房颤患者心脏结构及心脏功能，减少新发房颤及降低房颤复发率。本文综述了沙库巴曲缬沙坦对于房颤治疗的作用机制及疗效的研究进展。Atrial fibrillation (AF) is one of the most common clinical arrhythmias that significantly increases the risk of cardiovascular events and death. At present, there are radiofrequency ablation and antiarrhythmic drug therapy to maintain the sinus rhythm of atrial fibrillation. However, both drug and surgical treatments have high recurrence rates, making it difficult to achieve satisfactory therapeutic outcomes. As an angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan can inhibit neprilysin and block angiotensin receptors at the same time. Studies have shown that sacubitril/valsartan in the treatment of heart failure and hypertension can help improve heart structure and heart function in patients with atrial fibrillation, reduce new atrial fibrillation and reduce the recurrence rate of atrial fibrillation. This article reviews the research progress on the mechanism of action and efficacy of sacubitril/valsartan in the treatment of atrial fibrillation.